Taipei Medical University, Taiwan
Distinguished Professor and Vice-Dean at the College of Biomedical Engineering
Thierry Burnouf, PhD, is a Distinguished Professor and Vice-Dean at the College of Biomedical Engineering, Taipei Medical University, Taiwan. He established and leads a research lab focusing on platelets and extracellular vesicles for regenerative medicine, cell therapy, and drug delivery. He also holds an Honorary Professorship at the University of Lille, France. Prior to working in Taiwan, Thierry Burnouf was head of R&D, Director of plasma fractionation at CRTS-Lille, and Scientific Director of LFB, in France, and Vice-President of Haemonetics Corporation, USA.
Thierry has published over 350 scientific papers on the development and clinical applications of therapeutic products derived from human plasma and platelets, and is the inventor of more than 25 patent families related to blood product technologies. He is a member of the editorial board for Vox Sanguinis, Platelets, Biologicals, Transfusion Clinique et Biologique, and others. He serves as Treasurer of the Working Party for Cellular Therapies and as the Secretary of the Working Party for Global Blood Safety of the International Society of Blood Transfusion (ISBT), and is an advisor to the WHO, contributing to several guidelines on blood product quality and safety.
Thierry Burnouf was awarded the 2024 Presidential Award of the ISBT, the 2021 Outstanding Research Award from Taiwan's Ministry of Science and Technology, and the 2019 International Plasma and Plasma Fractionation Association (IPFA) Award for his translation work on therapeutic blood products.
Nora is a Principal in the EMEA Medical Evidence Practice at IQVIA where she leads RWE consulting and evidence generation studies to improve healthcare through innovate real-world insights. Trained as an epidemiologist, she started her career in public health at...
En savoir +Dr Anaïck Moisan, PharmD and PhD, is the pharmacist responsible for the production and the release of ATMP used in regenerative medicine and clinical trials, in the Cell Therapy and Engineering Unit of EFS Rhône Alpes, based in St Ismier,...
En savoir +Since more than 20 years, I have been interested in the field of the T-cell response either after hematopoietic stem cell allo-transplantation or in the anti-tumor effect to modulate Graft versus Host disease (GvHD) or to initiate anti-tumoral effects (Graft...
En savoir +After a master's degree in genetics and a Ph.D. on the role of Gas6 protein and precursor cells in steatohepatitis and hepatic fibrosis, Agnès advised companies in many sectors, particularly in industry, as a consultant in innovation financing. She was...
En savoir +Nathalie Labarriere is Inserm Research Director, in charge of the team 3 « Anti-tumor immunosurveillance and immunotherapy» and deputy director of the INCIT Unit (Immunology and new concepts in Immunotherapy). She started working in 1990 on tumor immunology in Nantes...
En savoir +Dr Olivier Humbey (PhD) is a Business Developer at IQVIA offering international Real World Data solutions to Biotechs at each stage of their product life cycle development (from early clinical to post-marketing). He works strategically with cross department services to...
En savoir +Jens Hasskarl is the chief medical officer of advesya, a French startup focused on developing lifesaving therapies. Prior to joining advesya, he was the chief medical officer of Tigen Pharma SA, a Swiss startup developing cellular therapies to fight solid...
En savoir +Dr. Julio Delgado is the Head of the Oncoimmunotherapy Unit and consultant haematologist at Hospital Clínic, Barcelona (HCB), researcher at IDIBAPS Biomedical Research Institute, and associate professor at the University of Barcelona. He has been involved in the clinical development...
En savoir +Dr. Dror Mevorach is a Full Professor and Director of the Rheumatology-Immunology-Allergology Institute at Hadassah Medical Center, affiliated with the Hebrew University in Jerusalem, Israel. He obtained his medical degree cum laude from the Technion Institute, Haifa, Israel, in 1988....
En savoir +Dr. Christian G. Figueroa-Espada is a distinguished biomedical engineer and cancer researcher dedicated to advancing therapeutic strategies through innovative nanotechnology and interdisciplinary approaches. He completed his Ph.D. in Bioengineering at the University of Pennsylvania, where his research focused on developing...
En savoir +Gavin joined MabDesign in 2019 and currently holds the position of Head of Scientific Affairs & Business Intelligence. In this role, Gavin oversees the strategic development and implementation of scientific initiatives including MabDesign’s Watchs editions, our multiple types of scientific...
En savoir +Dr. Jaime Fuentealba obtained his PhD in Neuroscience in 2017 from Sorbonne Université, working at the Brain and Spine Institute in Paris. He then joined the team of Dr. Sebastian Amigorena at Institut Curie as a post-doctoral fellow and contributed...
En savoir +Mathilde Girard is a stem cell specialist, specialized in bioproduction and automation for cell therapy applications. After a PhD in Human Genetics she specialized in pluripotent stem cells applications at the I-Stem institute in Evry. She notably led a research...
En savoir +Susanne Behlke, PhD serves currently as Chief Scientific Officer at Med’Inn’Pharma applying more than 15 years of clinical research, early and late stage drug development experiences, which she gained in positions within the pharmaceutical industry working at companies like EUROFINS...
En savoir +Prof de Pouvourville has graduated from Ecole Polytechnique in 1973 Formerly, he has led a career as a researcher in the field of health care economics and management, at Ecole polytechnique, at the French National School of Public Health and...
En savoir +European Regulation (EC) No 1394/2007 created a new class of drugs in 2007 called : “Advanced Therapy Medicinal Products”, resulting from cellular and tissue engineering, genetic manipulation, and possibly combined with medical devices. More than fifteen years after the implementation...
En savoir +From the beginning of my career in 2001 at the “Etablissement Français du Sang” (EFS, BFC, Besançon), I became interested in translational research and more particularly to modulate the T cells lymphocyte response, such as T cells involved in host-graft-tumor...
En savoir +President-Elect and Board of Directors member of the International Society of Cell and Gene Therapy (ISCT) from May 2022. Previously Chief Commercialization Officer and Chair of the ISCT Commercialization Committee (2014-2020) leading the expansion of the industrial community, strengthening the...
En savoir +Doctor in Immunology, researcher at and former director of the Autoimmunity-Transplantation-Inflammation research team at the INSERM-Univ Franche Comté-EFS Joint Research Unit 1098 RIGHT in Besançon (FR) for the last 10 years, Dr Perruche is now the founder and CEO of...
En savoir +JCM is the Associate Director for Tissues, Cells and Advanced Therapies (TCAT) at the SNBTS and an Honorary Reader at University of Edinburgh. As an experienced experimental haematologist and stem cell biologist Jo’s focus is the assessment, development and translation...
En savoir +After studying biology at the University of Sciences in Besançon, Sylvie defended her thesis based on cytogenetic and molecular prenatal diagnostic tools in Pr. Bresson's cytogenetics laboratories in Besançon. Then she went to Montreal, Quebec, as a laboratory coordinator at...
En savoir +Dr GUILLONNEAU is Director of Research CNRS, head of team 2 at the Center of Research in Transplantation and Translational Immunology (CR2TI) in Nantes, France and director of the FOCIS Center of Excellence Nantes University. After a Postdoc in the...
En savoir +Stéphane Maddens is the founder and CEO of Vetbiobank, a clinical-stage biotech based in Lyon (France) and specialised in developing and manufacturing cell-based drugs for animal health. He holds a pharmacy degree specialised in cell therapy applied to hemato-oncology diseases...
En savoir +Julien Branchu focused his scientific career on the discovery of innovative therapeutic targets that could improve the daily lives of patients. After several internships in neuroscience field, he joined Pr. F. Charbonnier's group for his PhD. Using in vitro and...
En savoir +John De Vos is Professor of Embryology, Histology and Regenerative Medicine at the Faculty of Medicine of Montpellier, and head of the Cellular and Tissue Engineering Department of the University Hospital Center (CHU) of Montpellier. His research, at the Research...
En savoir +Sebastian Amigorena is “Directeur de Recherche Classe Exceptionnelle” at CNRS, Director of the “Center of Immunotherapy for cancers” and the “Immune responses and cancer” Team at Institut Curie (Paris, France), in the Immunology Department "Immunity and Cancer" that he created...
En savoir +Geoffrey joined MabDesign in 2017 and holds the position of Corporate Development Manager. His role involves developing strategic partnerships for the organisation and coordinating MabDesign's offerings, both internally and externally. In the field of research, he supports industry players by...
En savoir +MD degree, Freiburg University Supervisor of MD thesis: Radvan Urbanek, magna cum laude DEA immunology, Institut Pasteur, Paris Supervisor: Pierre Andre Cazenave PhD Immunology, Universite Paris VII Supervisor: Raif Geha, summa cum laude Residency in Pediatrics, Children’s Hospital Boston Fellowship...
En savoir +